Genital antibody response to a parenteral gonococcal pilus vaccine.

A parenteral gonococcal pilus vaccine which has previously been shown to be safe and antigenic also results in the production of specific local genital antibody. All three major antibody classes were present in the local secretions, but immunoglobulin A predominated, a portion of which is dimeric 11S immunoglobulin A. This mucosal antibody is also capable of blocking the attachment of gonococci to epithelial cells. The antibody cross-reacted with five heterologous pili in a solid-phase radioimmunoassay. These results are encouraging and suggest that a gonococcal pilus vaccine may be efficacious in preventing gonorrhea.
AuthorsD McChesney, E C Tramont, J W Boslego, J Ciak, J Sadoff, C C Brinton
JournalInfection and immunity (Infect Immun) Vol. 36 Issue 3 Pg. 1006-12 (Jun 1982) ISSN: 0019-9567 [Print] UNITED STATES
PMID6124502 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Immunoglobulin A
  • Immunoglobulin A, Secretory
  • Immunoglobulin G
  • Adult
  • Antibodies, Bacterial (biosynthesis)
  • Bacterial Vaccines (administration & dosage, immunology)
  • Cell Adhesion
  • Cross Reactions
  • Female
  • Fimbriae, Bacterial (immunology)
  • Humans
  • Immunoglobulin A (biosynthesis)
  • Immunoglobulin A, Secretory (biosynthesis)
  • Immunoglobulin G (biosynthesis)
  • Injections, Intramuscular
  • Male
  • Neisseria gonorrhoeae (immunology)
  • Semen (immunology)
  • Vagina (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: